Carregant...
Curaxin CBL0137 has the potential to reverse HIV-1 latency
A cure for human immunodeficiency virus type-1 (HIV-1) has been hampered by the limitation of current combination antiretroviral therapy (cART) to address the latent reservoirs in HIV-1 patients. One strategy proposed to eradicate these reservoirs is the “shock and kill” approach, where latency-reve...
Guardat en:
| Publicat a: | J Med Virol |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6599568/ https://ncbi.nlm.nih.gov/pubmed/30989696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25487 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|